Immunic (NASDAQ:IMUX) Upgraded by StockNews.com to “Hold”

Immunic (NASDAQ:IMUX) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

Separately, Brookline Capital Management restated a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Friday, April 5th.

Immunic Price Performance

Immunic stock traded down $0.09 during trading hours on Friday, hitting $1.18. The company had a trading volume of 365,394 shares, compared to its average volume of 876,208. The firm has a market capitalization of $106.12 million, a P/E ratio of -0.56 and a beta of 2.07. The firm’s fifty day moving average is $1.33 and its 200-day moving average is $1.27. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $3.11.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.03. Analysts anticipate that Immunic will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. LPL Financial LLC acquired a new position in shares of Immunic during the 2nd quarter worth $28,000. MetLife Investment Management LLC bought a new stake in shares of Immunic during the 1st quarter worth $134,000. JPMorgan Chase & Co. boosted its holdings in shares of Immunic by 21.2% during the 1st quarter. JPMorgan Chase & Co. now owns 13,649 shares of the company’s stock worth $154,000 after buying an additional 2,387 shares during the period. Two Sigma Securities LLC bought a new stake in shares of Immunic during the 2nd quarter worth $36,000. Finally, Wolverine Trading LLC bought a new stake in Immunic in the 2nd quarter valued at $42,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.